LogicBio Therapeutics (LOGC) Stock Forecast, Price & News

LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions

Is LogicBio Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LogicBio Therapeutics stock.
View analyst ratings for LogicBio Therapeutics or view top-rated stocks.

Are investors shorting LogicBio Therapeutics?

LogicBio Therapeutics saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 50,000 shares, a decline of 60.9% from the April 15th total of 127,800 shares. Based on an average daily trading volume, of 1,230,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.3% of the shares of the stock are short sold.
View LogicBio Therapeutics' Short Interest.

When is LogicBio Therapeutics' next earnings date?

LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for LogicBio Therapeutics.

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) posted its earnings results on Monday, May, 16th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. LogicBio Therapeutics had a negative net margin of 739.91% and a negative trailing twelve-month return on equity of 95.00%.
View LogicBio Therapeutics' earnings history.

What price target have analysts set for LOGC?

5 analysts have issued twelve-month target prices for LogicBio Therapeutics' stock. Their forecasts range from $6.00 to $16.00. On average, they expect LogicBio Therapeutics' stock price to reach $11.25 in the next year. This suggests a possible upside of 2,547.1% from the stock's current price.
View analysts' price targets for LogicBio Therapeutics or view top-rated stocks among Wall Street analysts.

Who are LogicBio Therapeutics' key executives?

LogicBio Therapeutics' management team includes the following people:

• Mr. Frederic Chereau M.B.A., Pres, CEO & Director (Age 55, Pay $677.2k) (LinkedIn Profile)
• Dr. Mark A. Kay M.D., Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 63, Pay $85k)
• Ms. Mariana Nacht Ph.D., Chief Scientific Officer (Age 58, Pay $429.64k)
• Dr. Kyle Chiang Ph.D., Consultant (Age 42, Pay $348.85k)
• Dr. Leszek Lisowski M.B.A., Ph.D., Co-Founder & Member of Scientific Advisory Board
• Dr. Adi Barzel Ph.D., Co-Founder
• Ms. Cecilia Jones, Chief Financial Officer (Age 47)
• Dr. Matthias Hebben, Global VP & Head of Technology Devel.
• Ms. Andrea Paul, Gen. Counsel & Corp. Sec.
• Ms. Grace Lochhead, VP & Head of HR

Who are some of LogicBio Therapeutics' key competitors?

Some companies that are related to LogicBio Therapeutics include Cabaletta Bio (CABA), Entera Bio (ENTX), CASI Pharmaceuticals (CASI), IN8bio (INAB), Protalix BioTherapeutics (PLX), Protalix BioTherapeutics (PLX), Aligos Therapeutics (ALGS), Xtant Medical (XTNT), PharmaCyte Biotech (PMCB), Pluristem Therapeutics (PSTI), AIM ImmunoTech (AIM), MiNK Therapeutics (INKT), Evaxion Biotech A/S (EVAX), TRACON Pharmaceuticals (TCON) and Applied Genetic Technologies (AGTC).
View all of LOGC's competitors.

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an initial public offering on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager.

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

Who are LogicBio Therapeutics' major shareholders?

LogicBio Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.39%), Vanguard Group Inc. (0.98%), Harbor Capital Advisors Inc. (0.69%), Virtu Financial LLC (0.22%), Acadian Asset Management LLC (0.15%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own LogicBio Therapeutics stock include Bioscience Plc Arix, Daniel Gruskin, Frederic Chereau, Kyle Chiang and Orbimed Advisors Llc.
View institutional ownership trends for LogicBio Therapeutics.

Which major investors are selling LogicBio Therapeutics stock?

LOGC stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Harbor Capital Advisors Inc., and Simplex Trading LLC.
View insider buying and selling activity for LogicBio Therapeutics or view top insider-selling stocks.

Which major investors are buying LogicBio Therapeutics stock?

LOGC stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Virtu Financial LLC, and Acadian Asset Management LLC.
View insider buying and selling activity for LogicBio Therapeutics or or view top insider-buying stocks.

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $0.43.

How much money does LogicBio Therapeutics make?

LogicBio Therapeutics has a market capitalization of $14.01 million and generates $5.41 million in revenue each year. The company earns $-40.03 million in net income (profit) each year or ($1.240010) on an earnings per share basis.

How many employees does LogicBio Therapeutics have?

LogicBio Therapeutics employs 62 workers across the globe.

What is LogicBio Therapeutics' official website?

The official website for LogicBio Therapeutics is www.logicbio.com.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The company can be reached via phone at (617) 245-0399 or via email at [email protected].